JP2017214397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017214397A5 JP2017214397A5 JP2017130030A JP2017130030A JP2017214397A5 JP 2017214397 A5 JP2017214397 A5 JP 2017214397A5 JP 2017130030 A JP2017130030 A JP 2017130030A JP 2017130030 A JP2017130030 A JP 2017130030A JP 2017214397 A5 JP2017214397 A5 JP 2017214397A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- composition
- acid residues
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- 125000000539 amino acid group Chemical group 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108010014603 Leukocidins Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 239000005017 polysaccharide Substances 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 1
- 102100026189 Beta-galactosidase Human genes 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- FWPKHBSTLJXXIA-CATQOQJWSA-N CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O FWPKHBSTLJXXIA-CATQOQJWSA-N 0.000 claims 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 102100035882 Catalase Human genes 0.000 claims 1
- 108010053835 Catalase Proteins 0.000 claims 1
- 229940105129 Chemotaxis inhibitor Drugs 0.000 claims 1
- 101000620271 Chlamydia pneumoniae Probable outer membrane protein pmp7 Proteins 0.000 claims 1
- 108010065152 Coagulase Proteins 0.000 claims 1
- 108090000056 Complement factor B Proteins 0.000 claims 1
- 102000003712 Complement factor B Human genes 0.000 claims 1
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 claims 1
- 101710121036 Delta-hemolysin Proteins 0.000 claims 1
- 108090000204 Dipeptidase 1 Proteins 0.000 claims 1
- 101710146739 Enterotoxin Proteins 0.000 claims 1
- 101710128530 Fibrinogen-binding protein Proteins 0.000 claims 1
- 108010040721 Flagellin Proteins 0.000 claims 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 claims 1
- 108010013639 Peptidoglycan Proteins 0.000 claims 1
- 101710124951 Phospholipase C Proteins 0.000 claims 1
- 102100027287 Serpin H1 Human genes 0.000 claims 1
- 108050008290 Serpin H1 Proteins 0.000 claims 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 1
- 101710145796 Staphylokinase Proteins 0.000 claims 1
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 claims 1
- 102000009843 Thyroglobulin Human genes 0.000 claims 1
- 108010034949 Thyroglobulin Proteins 0.000 claims 1
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 claims 1
- 101710182223 Toxin B Proteins 0.000 claims 1
- 101710182532 Toxin a Proteins 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 102000006635 beta-lactamase Human genes 0.000 claims 1
- 229940098773 bovine serum albumin Drugs 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 239000002819 chemotaxis inhibitor Substances 0.000 claims 1
- 210000000991 chicken egg Anatomy 0.000 claims 1
- 229960003983 diphtheria toxoid Drugs 0.000 claims 1
- 108010064033 elastin-binding proteins Proteins 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000147 enterotoxin Substances 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- 102000025748 fibrinogen binding proteins Human genes 0.000 claims 1
- 102000036072 fibronectin binding proteins Human genes 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- 239000003228 hemolysin Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 claims 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 229940092253 ovalbumin Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000447 polyanionic polymer Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 229960002175 thyroglobulin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498596P | 2011-06-19 | 2011-06-19 | |
| US61/498,596 | 2011-06-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517100A Division JP6170913B2 (ja) | 2011-06-19 | 2012-06-19 | 黄色ブドウ球菌感染および関連状態を治療および予防する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018231287A Division JP6758363B2 (ja) | 2011-06-19 | 2018-12-11 | 黄色ブドウ球菌感染および関連状態を治療および予防する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017214397A JP2017214397A (ja) | 2017-12-07 |
| JP2017214397A5 true JP2017214397A5 (enExample) | 2018-03-01 |
| JP6452765B2 JP6452765B2 (ja) | 2019-01-16 |
Family
ID=47423177
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517100A Active JP6170913B2 (ja) | 2011-06-19 | 2012-06-19 | 黄色ブドウ球菌感染および関連状態を治療および予防する方法 |
| JP2017130030A Active JP6452765B2 (ja) | 2011-06-19 | 2017-07-03 | 黄色ブドウ球菌感染および関連状態を治療および予防する方法 |
| JP2018231287A Active JP6758363B2 (ja) | 2011-06-19 | 2018-12-11 | 黄色ブドウ球菌感染および関連状態を治療および予防する方法 |
| JP2020146494A Active JP7129451B2 (ja) | 2011-06-19 | 2020-09-01 | 黄色ブドウ球菌感染および関連状態を治療および予防する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517100A Active JP6170913B2 (ja) | 2011-06-19 | 2012-06-19 | 黄色ブドウ球菌感染および関連状態を治療および予防する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018231287A Active JP6758363B2 (ja) | 2011-06-19 | 2018-12-11 | 黄色ブドウ球菌感染および関連状態を治療および予防する方法 |
| JP2020146494A Active JP7129451B2 (ja) | 2011-06-19 | 2020-09-01 | 黄色ブドウ球菌感染および関連状態を治療および予防する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US9091689B2 (enExample) |
| EP (3) | EP3777885A1 (enExample) |
| JP (4) | JP6170913B2 (enExample) |
| KR (1) | KR102050267B1 (enExample) |
| CN (3) | CN103717234A (enExample) |
| AU (1) | AU2012273123C1 (enExample) |
| BR (2) | BR122020000047B1 (enExample) |
| CA (1) | CA2839554C (enExample) |
| CL (2) | CL2013003650A1 (enExample) |
| DK (1) | DK3403669T3 (enExample) |
| ES (2) | ES2812181T3 (enExample) |
| HR (1) | HRP20201265T1 (enExample) |
| HU (1) | HUE051832T2 (enExample) |
| IL (2) | IL229922B (enExample) |
| LT (1) | LT3403669T (enExample) |
| MX (2) | MX340446B (enExample) |
| NZ (1) | NZ764564A (enExample) |
| RU (1) | RU2635462C2 (enExample) |
| SI (1) | SI3403669T1 (enExample) |
| WO (1) | WO2012177658A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103717234A (zh) | 2011-06-19 | 2014-04-09 | 纽约大学 | 治疗和预防金黄色葡萄球菌感染及相关病状的方法 |
| US9657103B2 (en) | 2012-05-02 | 2017-05-23 | New York University | Methods of treating and preventing Staphylococcus aureus infections and associated conditions |
| EP3441474B1 (en) * | 2013-06-18 | 2020-07-22 | New York University | Pharmaceutical compositions containing a mutated leukocidin e |
| RU2016119052A3 (en) * | 2013-10-17 | 2018-09-10 | Arsanis Biosciences Gmbh | Cross-reactive Staphylococcus aureus antibody sequences |
| WO2015089073A2 (en) * | 2013-12-09 | 2015-06-18 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
| BE1022875B1 (fr) * | 2014-03-26 | 2016-09-30 | Glaxosmithkline Biologicals S.A. | Compositions pour une immunisation contre staphylococcus aureus |
| CA2956429A1 (en) * | 2014-08-12 | 2016-02-18 | Arsanis Biosciences Gmbh | Predicting s. aureus disease |
| US20180179267A1 (en) * | 2015-04-17 | 2018-06-28 | Arsanis Biosciences Gmbh | Anti-staphylococcus aureus antibody combination preparation |
| EP3302532A4 (en) * | 2015-06-05 | 2019-01-09 | New York University | COMPOSITIONS AND METHODS FOR BIOLOGICAL ACTIVE AGGREGATES AGAINST STAPHYLOKOKEN |
| CN105641689B (zh) * | 2016-01-21 | 2024-09-10 | 浙江海隆生物科技股份有限公司 | 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用 |
| US11104724B2 (en) | 2016-05-23 | 2021-08-31 | New York University | Compositions and methods for antibodies targeting staphylococcal leukotoxins |
| US11324815B2 (en) | 2016-10-21 | 2022-05-10 | Socpra—Sciences et Genie, S.E.C. | Vaccine constructs and uses thereof against Staphylococcus infections |
| JP7211626B2 (ja) * | 2017-02-20 | 2023-01-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 無症候性脳虚血に関する血清学的アッセイ |
| CN107224575B (zh) * | 2017-03-06 | 2018-11-09 | 浙江海隆生物科技有限公司 | 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用 |
| CN106749652A (zh) * | 2017-03-14 | 2017-05-31 | 天津喜诺生物医药有限公司 | 一种金黄色葡萄球菌肽聚糖的多克隆抗体 |
| EP3720458A4 (en) | 2017-12-05 | 2021-12-08 | BioPlx, Inc. | METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION |
| BR112021001214A2 (pt) | 2018-07-24 | 2021-04-27 | Medimmune, Llc | anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus |
| BR112021016996A8 (pt) * | 2019-02-28 | 2022-11-22 | Dandi Bioscience Inc | Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana |
| CN111423516B (zh) * | 2020-04-01 | 2022-02-11 | 广州佰斯伦医疗器械有限公司 | 一种蛋白及其在创口修复及抑菌中的应用 |
| CN111398194B (zh) * | 2020-04-10 | 2020-11-03 | 上海华茂药业有限公司 | 一种用于测定艾考糊精中肽聚糖的方法 |
| CN112851770B (zh) * | 2021-02-05 | 2022-10-04 | 中国人民解放军陆军军医大学 | 一种用于诊断或防治金黄色葡萄球菌感染的α溶血素抗原表位肽及其应用 |
| CN114317787A (zh) * | 2021-12-29 | 2022-04-12 | 成都大学 | 吸附磁珠及其试剂盒和用途以及检测金黄色葡萄球菌的方法 |
| CN115991766B (zh) * | 2023-03-13 | 2025-01-14 | 广州庆毅生物医药科技有限公司 | 一种细菌抗原检测试剂盒及其应用 |
| CN119431528B (zh) * | 2024-10-28 | 2025-10-14 | 中国人民解放军陆军军医大学 | 一种金黄色葡萄球菌毒素LukG抗原表位肽及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1121135B1 (en) | 1998-09-14 | 2009-01-28 | Nabi Biopharmaceuticals | Compositions of beta-glucans and specific immunoglobulins |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| AU2002306849A1 (en) | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| US20030171563A1 (en) | 2001-05-18 | 2003-09-11 | Mcnamara Peter J. | Regulators of bacterial virulence factor expression |
| US7288654B2 (en) | 2003-02-07 | 2007-10-30 | Takeda Pharmaceutical Company Ltd | Fused-ring pyridine derivative, process for producing the same, and use |
| IL157398A0 (en) | 2003-08-14 | 2004-02-19 | Hadasit Med Res Service | Pharmaceutical compositions comprising ccr5 antagonists |
| US7622125B2 (en) | 2004-05-05 | 2009-11-24 | Novartis Vaccines And Diagnostics, Inc. | Polycistronic HIV vector constructs |
| EP2893938B1 (en) | 2004-09-22 | 2019-03-06 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against Staphylococcei |
| WO2007062150A2 (en) | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Leukotoxin compositions and therapeutic methods |
| EP1986673A2 (en) | 2006-02-13 | 2008-11-05 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health and Human Services | Methods and compositions related to ghs-r antagonists |
| EP2043690A1 (en) * | 2006-06-12 | 2009-04-08 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| KR20090013827A (ko) | 2006-06-12 | 2009-02-05 | 화이자 프로덕츠 인크. | Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제 |
| JP2008013447A (ja) * | 2006-07-03 | 2008-01-24 | Juntendo | 毒素検出方法 |
| WO2008099278A2 (en) | 2007-02-15 | 2008-08-21 | Pfizer Limited | Pharmaceutical compositions and methods for ccr5 antagonists |
| CN102448482A (zh) | 2009-03-27 | 2012-05-09 | 范安德尔研究所 | 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法 |
| ES2565377T3 (es) * | 2009-04-14 | 2016-04-04 | Glaxosmithkline Biologicals Sa | Composiciones para inmunización contra Staphylococcus aureus |
| US8409584B2 (en) | 2009-05-05 | 2013-04-02 | New York University | Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
| EP2488198B1 (en) | 2009-10-13 | 2016-09-28 | Rutgers, the State University of New Jersey | Treatment and diagnosis of autoimmune disorders |
| KR20190133290A (ko) * | 2010-05-05 | 2019-12-02 | 뉴욕 유니버시티 | 스타필로코커스 아우레우스 류코시딘, 치료 조성물 및 그것의 용도 |
| CN103717234A (zh) * | 2011-06-19 | 2014-04-09 | 纽约大学 | 治疗和预防金黄色葡萄球菌感染及相关病状的方法 |
| BR112013032911A2 (pt) * | 2011-06-19 | 2017-01-24 | Univ New York | leucotoxina e/d como um novo agente anti-inflamatório e microbicida |
-
2012
- 2012-06-19 CN CN201280039370.5A patent/CN103717234A/zh active Pending
- 2012-06-19 BR BR122020000047-3A patent/BR122020000047B1/pt active IP Right Grant
- 2012-06-19 EP EP20185534.3A patent/EP3777885A1/en active Pending
- 2012-06-19 CN CN201410532443.5A patent/CN104474531A/zh active Pending
- 2012-06-19 HU HUE18182774A patent/HUE051832T2/hu unknown
- 2012-06-19 WO PCT/US2012/043179 patent/WO2012177658A2/en not_active Ceased
- 2012-06-19 MX MX2013014640A patent/MX340446B/es active IP Right Grant
- 2012-06-19 JP JP2014517100A patent/JP6170913B2/ja active Active
- 2012-06-19 NZ NZ764564A patent/NZ764564A/en unknown
- 2012-06-19 CA CA2839554A patent/CA2839554C/en active Active
- 2012-06-19 CN CN201910111454.9A patent/CN109893644A/zh active Pending
- 2012-06-19 KR KR1020147001089A patent/KR102050267B1/ko active Active
- 2012-06-19 BR BR112013032774A patent/BR112013032774B1/pt active IP Right Grant
- 2012-06-19 DK DK18182774.2T patent/DK3403669T3/da active
- 2012-06-19 AU AU2012273123A patent/AU2012273123C1/en active Active
- 2012-06-19 ES ES18182774T patent/ES2812181T3/es active Active
- 2012-06-19 LT LTEP18182774.2T patent/LT3403669T/lt unknown
- 2012-06-19 MX MX2016004832A patent/MX357938B/es unknown
- 2012-06-19 US US13/527,436 patent/US9091689B2/en active Active
- 2012-06-19 EP EP18182774.2A patent/EP3403669B1/en active Active
- 2012-06-19 EP EP12801920.5A patent/EP2720714B1/en active Active
- 2012-06-19 ES ES12801920.5T patent/ES2684088T3/es active Active
- 2012-06-19 RU RU2014101488A patent/RU2635462C2/ru active
- 2012-06-19 SI SI201231821T patent/SI3403669T1/sl unknown
-
2013
- 2013-12-11 IL IL229922A patent/IL229922B/en active IP Right Grant
- 2013-12-19 CL CL2013003650A patent/CL2013003650A1/es unknown
-
2015
- 2015-06-11 US US14/736,751 patent/US9481723B2/en active Active
-
2016
- 2016-09-23 US US15/273,914 patent/US9783597B2/en active Active
-
2017
- 2017-07-03 JP JP2017130030A patent/JP6452765B2/ja active Active
- 2017-09-08 US US15/699,345 patent/US10202440B2/en active Active
-
2018
- 2018-04-24 IL IL258886A patent/IL258886A/en unknown
- 2018-12-11 JP JP2018231287A patent/JP6758363B2/ja active Active
-
2019
- 2019-01-07 US US16/241,664 patent/US10669329B2/en active Active
- 2019-07-23 CL CL2019002056A patent/CL2019002056A1/es unknown
-
2020
- 2020-04-28 US US16/860,716 patent/US11078258B2/en active Active
- 2020-08-11 HR HRP20201265TT patent/HRP20201265T1/hr unknown
- 2020-09-01 JP JP2020146494A patent/JP7129451B2/ja active Active
-
2021
- 2021-07-06 US US17/368,566 patent/US20210340228A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017214397A5 (enExample) | ||
| HRP20201265T1 (hr) | Postupci liječenja i sprječavanja infekcija sa staphilococcus aureus i povezanih stanja | |
| JP2014520149A5 (enExample) | ||
| RU2508126C2 (ru) | Композиции для иммунизации против staphylococcus aureus | |
| ES2659925T3 (es) | Composición farmacéutica y vacuna contra infecciones estafilocócicas | |
| CA2530363C (en) | Carrier proteins for vaccines | |
| JP2015214545A5 (enExample) | ||
| RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
| RU2011140858A (ru) | Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях | |
| WO2011126811A3 (en) | High level expression of recombinant toxin proteins | |
| JP2014514363A5 (enExample) | ||
| JP2016522259A5 (enExample) | ||
| MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| RU2014122163A (ru) | Комбинации, включающие сахарид пневмококка серотипа 14 | |
| KR102266346B1 (ko) | 치료에 사용하기 위한 면역원성 조성물 | |
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
| HRP20181782T2 (hr) | Peptidno cjepivo pcsk9 | |
| TW201639874A (zh) | 豬胸膜肺炎放線桿菌重組毒素蛋白及其應用 | |
| WO2011025344A3 (ko) | 소의 병원성 대장균의 부착인자가 형질전환된 약독화 살모넬라균 변이주 및 이를 포함하는 소의 대장균증 및 살모넬라균증의 예방 및 치료용 백신조성물 | |
| US12280097B2 (en) | Optimized cell-free synthesis of invasion plasmid antigen B and related compositions and methods of use | |
| WO2017011338A1 (en) | Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use | |
| SI2925355T1 (en) | Antigens and combinations of Pseudomonas antigens |